Evidence map›Paper›PMID 38416029›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2024

Granzyme F: Exhaustion Marker and Modulator of Chimeric Antigen Receptor T Cell-Mediated Cytotoxicity.

Zachary L Z Hay, Dale D Kim, Jennifer M Cimons, Jennifer R Knapp, M Eric Kohler, Mary Quansah, Tiffany M Zúñiga, Faye A Camp, Mayumi Fujita, Xiao-Jing Wang and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Zachary L Z HayDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO.ORCID 0000-0001-6503-0647
Dale D KimDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO.ORCID 0000-0003-1987-3680
Jennifer M CimonsDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, CO.ORCID 0000-0002-8111-8697
Jennifer R KnappCenter for Genes, Environment and Health, National Jewish Health, Denver, CO.ORCID 0000-0003-4342-5378
M Eric KohlerDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, CO.ORCID 0000-0002-1181-0418
Mary QuansahDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO.
Tiffany M ZúñigaDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO.ORCID 0000-0002-8511-479X
Faye A CampDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO.ORCID 0000-0002-0796-9346
Mayumi FujitaDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO.ORCID 0000-0002-1498-1925
Xiao-Jing WangDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO.ORCID 0000-0001-8695-7361
Brian P O'ConnorCenter for Genes, Environment and Health, National Jewish Health, Denver, CO.ORCID 0000-0002-4776-2622
Jill E SlanskyDepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO.ORCID 0000-0003-3820-1724
University of Colorado Denver · USNational Jewish Health · USVeterans Health Administration · USChildren's Hospital Colorado · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Paul Calabresis Award in Clinical Oncology ResearchK12CA086913 · NCI · UNIVERSITY OF COLORADO DENVER · PI VIRGINIA F. BORGES, Jill E Slansky · 2000 to 2026
$17.8M
TRAINING PROGRAM IN IMMUNOLOGYT32AI007405 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Laurel L Lenz, Raul Martin Torres · 1991 to 2026
$10.5M
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.P50CA261605 · NCI · UNIVERSITY OF COLORADO DENVER · PI JIMENO, ANTONIO, WANG, XIAO-JING · 2021 to 2025
$10.1M
Molecular Mechanisms of Immune ToleranceT32AI074491 · NIAID · NATIONAL JEWISH HEALTH · PI CAMBIER, JOHN C, PELANDA, ROBERTA · 2009 to 2023
$4.1M
Functional Activation of Low Affinity TILsR01CA226879 · NCI · UNIVERSITY OF COLORADO DENVER · PI SLANSKY, JILL E · 2019 to 2023
$2.1M
Cancer Research Experiences for Undergraduates (CREU)R25CA240122 · NCI · UNIVERSITY OF COLORADO DENVER · PI SCHWEPPE, REBECCA ELIZABETH · 2019 to 2024
$1.6M
NCI NIH HHS P30 CA046934NCI NIH HHS P50 CA261605NCI NIH HHS R01 CA226879NCI NIH HHS R25 CA240122NIAID NIH HHS T32 AI007405NIAID NIH HHS T32 AI074491
6 · The paper itself

Abstract

Granzymes are a family of proteases used by CD8 T cells to mediate cytotoxicity and other less-defined activities. The substrate and mechanism of action of many granzymes are unknown, although they diverge among the family members. In this study, we show that mouse CD8+ tumor-infiltrating lymphocytes (TILs) express a unique array of granzymes relative to CD8 T cells outside the tumor microenvironment in multiple tumor models. Granzyme F was one of the most highly upregulated genes in TILs and was exclusively detected in PD1/TIM3 double-positive CD8 TILs. To determine the function of granzyme F and to improve the cytotoxic response to leukemia, we constructed chimeric Ag receptor T cells to overexpress a single granzyme, granzyme F or the better-characterized granzyme A or B. Using these doubly recombinant T cells, we demonstrated that granzyme F expression improved T cell-mediated cytotoxicity against target leukemia cells and induced a form of cell death other than chimeric Ag receptor T cells expressing only endogenous granzymes or exogenous granzyme A or B. However, increasing expression of granzyme F also had a detrimental impact on the viability of the host T cells, decreasing their persistence in circulation in vivo. These results suggest a unique role for granzyme F as a marker of terminally differentiated CD8 T cells with increased cytotoxicity, but also increased self-directed cytotoxicity, suggesting a potential mechanism for the end of the terminal exhaustion pathway.

Indexed as

LeukemiaReceptors, Chimeric AntigenAnimalsCD8-Positive T-LymphocytesCytotoxicity, ImmunologicGranzymesMiceTumor MicroenvironmentGranzymesGzmf protein, mouseReceptors, Chimeric Antigen

Identifiers

PMID38416029
PMCPMC10984789
OpenAlexW4392232116

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.